Ovarian cancer ranks fifth with a 5-year survival of 40% for patients with advanced disease and remains the most lethal gynecologic malignancy among women [1]. Most patients with advanced disease undergo aggressive frontline treatments with surgery and adjuvant chemotherapy; however, 80% of patients ultimately recur within few months and develop chemoresistant disease [2]. Advances in traditional treatment regimens and addition bevacizumab as a targeted therapy have shown promising results with improved progression-free survival but overall survival rates still remains the unaltered.
http://www.lupinepublishers.com/igwhc/abstracts/IGWHC.MS.ID.000112.php
http://www.lupinepublishers.com/igwhc/fulltext/IGWHC.MS.ID.000112.php
http://www.lupinepublishers.com/igwhc/pdf/IGWHC.MS.ID.000112.pdf
No comments:
Post a Comment
Note: only a member of this blog may post a comment.